Revolution Medicines, Inc. Line of Credit Facility, Maximum Borrowing Capacity
Revolution Medicines, Inc. (RVMD) had Line of Credit Facility, Maximum Borrowing Capacity of $750.00 million as of 2025-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt
us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity · last filed 2026-08-05
- 2025-06-30: Line of Credit Facility, Maximum Borrowing Capacity $750.00M.
| Period end | Line of Credit Facility, Maximum Borrowing Capacity |
|---|---|
| 2025-06-30 | $750.00M 10-Q · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |